Company intelligence / Profile preview

Kraig Biocraft Laboratories

Ann Arbor, Michigan, United Stateskraiglabs.com ↗

Ownership: Private
Development stage: Commercial

Overview

Kraig Biocraft Laboratories has achieved multiple breakthroughs in recombinant spider silk technology, including the largest known gene insert into silkworms. The company has launched commercial-scale production at a new high-capacity facility and continues to innovate with more complex and high-performance spider silk fibers. Its products are being positioned for use in technical textiles, defense, luxury apparel, and industrial sectors but are not yet widely commercialized.

Modalities: Recombinant protein (spider silk)Genetically engineered biomaterial fibers
Industry: Non-Drug Biotech

Drug pipeline

1 asset

BAM-1

Commercial

Partnerships

Sigma-Aldrich/Merck partnership for genetically modified silkworms (historical)

Beyond the preview

Go deeper on Kraig Biocraft Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kraig Biocraft Laboratories.

Explore the full profile